Enhanced CTL response by controlled intracellular trafficking of antigen in dendritic cells following DNA vaccination

Journal of Controlled Release

Volumn 135, Issue 3, 2009, Pages 227-233

  Isaji, Keiko ^a   Kawase, Atsushi ^a   Matono, Mitsuhiro ^a   Guan, Xin ^a   Nishikawa, Makiya ^a   Takakura, Yoshinobu ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

CTL; Dendritic cell; DNA vaccine; Electroporation

Indexed keywords

ANTIGEN PEPTIDES; ANTIGEN PRESENTATIONS; CLASS I; COMPLETE FREUND'S ADJUVANTS; CTL; CYTOTOXIC T LYMPHOCYTES; DENDRITIC CELL; DNA VACCINATIONS; DNA VACCINE; ELECTROPORATION; ENDOPLASMIC RETICULUMS; EPITOPE PEPTIDES; IN-VITRO; IN-VIVO; INHIBITORY EFFECTS; INTERFERON GAMMAS; INTRACELLULAR TRAFFICKING; MAJOR HISTOCOMPATIBILITY COMPLEX CLASS; OVALBUMIN; PLASMID DNA (PDNA); SPLEEN CELLS; VECTORS ENCODING;

AMINES; ANTIGENS; CELL CULTURE; DENDRIMERS; DNA; ENCODING (SYMBOLS); GENES; IMMUNIZATION; VACCINES;

NUCLEIC ACIDS;

FREUND ADJUVANT; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OVA PROTEIN; OVALBUMIN; PEPTIDE; PLASMID DNA; PROTEIN; SERYLISOLEUCYLISOLEUCYLASPARAGINYLPHENYLALANYLGLUTAMYLLYSYLLEUCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA IMMUNIZATION; DNA TRANSFECTION; DNA VECTOR; ELECTROPORATION; ENDOPLASMIC RETICULUM; FEMALE; IMMUNE RESPONSE; IMMUNOASSAY; INTERFERON PRODUCTION; LYMPHOCYTE MIGRATION; LYMPHOMA; LYMPHOMA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPLEEN CELL;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS; CELL LINE; DENDRITIC CELLS; ELECTROPORATION; FEMALE; FREUND'S ADJUVANT; GENETIC VECTORS; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; OVALBUMIN; PLASMIDS; PROTEIN TRANSPORT; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA;

EID: 63649137436     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.01.026     Document Type: Article

References (50)

1. Tang D.C., DeVit M., and Johnston S.A. Genetic immunization is a simple method for eliciting an immune response. Nature 356 (1992) 152-154
2. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., Gromkowski S.H., Deck R.R., DeWitt C.M., Friedman A., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259 (1993) 1745-1749
3. Porgador A., Irvine K.R., Iwasaki A., Barber B.H., Restifo N.P., and Germain R.N. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J. Exp. Med. 188 (1998) 1075-1082
4. Shedlock D.J., and Weiner D.B. DNA vaccination: antigen presentation and the induction of immunity. J. Leukoc. Biol. 68 (2000) 793-806
5. Boyle J.S., Koniaras C., and Lew A.M. Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization. Int. Immunol. 9 (1997) 1897-1906
6. Rush C., Mitchell T., and Garside P. Efficient priming of CD4+ and CD8+ T cells by DNA vaccination depends on appropriate targeting of sufficient levels of immunologically relevant antigen to appropriate processing pathways. J. Immunol. 169 (2002) 4951-4960
7. Corr M., von Damm A., Lee D.J., and Tighe H. In vivo priming by DNA injection occurs predominantly by antigen transfer. J. Immunol. 163 (1999) 4721-4727
8. Cho J.H., Youn J.W., and Sung Y.C. Cross-priming as a predominant mechanism for inducing CD8(+) T cell responses in gene gun DNA immunization. J. Immunol. 167 (2001) 5549-5557
9. Akbari O., Panjwani N., Garcia S., Tascon R., Lowrie D., and Stockinger B. DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J. Exp. Med. 189 (1999) 169-178
10. Kim T.W., Hung C.F., Ling M., Juang J., He L., Hardwick J.M., Kumar S., and Wu T.C. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J. Clin. Invest. 112 (2003) 109-117
11. Pertmer T.M., Roberts T.R., and Haynes J.R. Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J. Virol. 70 (1996) 6119-6125
12. Feltquate D.M., Heaney S., Webster R.G., and Robinson H.L. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J. Immunol. 158 (1997) 2278-2284
13. Yoshida A., Nagata T., Uchijima M., Higashi T., and Koide Y. Advantage of gene gun-mediated over intramuscular inoculation of plasmid DNA vaccine in reproducible induction of specific immune responses. Vaccine 18 (2000) 1725-1729
14. Singh M., Briones M., Ott G., and O'Hagan D. Cationic microparticles: A potent delivery system for DNA vaccines. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 811-816
15. Denis-Mize K.S., Dupuis M., MacKichan M.L., Singh M., Doe B., O'Hagan D., Ulmer J.B., Donnelly J.J., McDonald D.M., and Ott G. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther. 7 (2000) 2105-2112
16. Golovina T.N., Wherry E.J., Bullock T.N., and Eisenlohr L.C. Efficient and qualitatively distinct MHC class I-restricted presentation of antigen targeted to the endoplasmic reticulum. J. Immunol. 168 (2002) 2667-2675
17. Langlade-Demoyen P., Garcia-Pons F., Castiglioni P., Garcia Z., Cardinaud S., Xiong S., Gerloni M., and Zanetti M. Role of T cell help and endoplasmic reticulum targeting in protective CTL response against influenza virus. Eur. J. Immunol. 33 (2003) 720-728
18. Kim S.J., Lee C., Lee S.Y., Kim I., Park J.S., Sasagawa T., Ko J.J., Park S.E., and Oh Y.K. Enhanced immunogenicity of human papillomavirus 16 L1 genetic vaccines fused to an ER-targeting secretory signal peptide and RANTES. Gene Ther. 10 (2003) 1268-1273
19. Michalek M.T., Grant E.P., Gramm C., Goldberg A.L., and Rock K.L. A role for the ubiquitin-dependent proteolytic pathway in MHC class I-restricted antigen presentation. Nature 363 (1993) 552-554
20. Iwasaki A., Dela Cruz C.S., Young A.R., and Barber B.H. Epitope-specific cytotoxic T lymphocyte induction by minigene DNA immunization. Vaccine 17 (1999) 2081-2088
21. Hung C.F., Cheng W.F., He L., Ling M., Juang J., Lin C.T., and Wu T.C. Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Res. 63 (2003) 2393-2398
22. Maecker H.T., Umetsu D.T., DeKruyff R.H., and Levy S. DNA vaccination with cytokine fusion constructs biases the immune response to ovalbumin. Vaccine 15 (1997) 1687-1696
23. Huebener N., Lange B., Lemmel C., Rammensee H.G., Strandsby A., Wenkel J., Jikai J., Zeng Y., Gaedicke G., and Lode H.N. Vaccination with minigenes encoding for novel 'self' antigens are effective in DNA-vaccination against neuroblastoma. Cancer Lett. 197 197 (2003) 211-217
24. Iliopoulos O., Kibel A., Gray S., and Kaelin Jr. W.G. Tumour suppression by the human von Hippel-Lindau gene product. Nat. Med. 1 (1995) 822-826
25. Kibel A., Iliopoulos O., DeCaprio J.A., and Kaelin Jr. W.G. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 269 (1995) 1444-1446
26. Deshaies R.J. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu. Rev. Cell Dev. Biol. 15 (1999) 435-467
27. Hershko A., and Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 67 (1998) 425-479
28. Laney J.D., and Hochstrasser M. Substrate targeting in the ubiquitin system. Cell 97 (1999) 427-430
29. Pickart C.M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70 (2001) 503-533
30. Shen Z., Reznikoff G., Dranoff G., and Rock K.L. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J. Immunol. 158 (1997) 2723-2730
31. Harding C.V., and Pfeifer J.D. Antigen expressed by Salmonella typhimurium is processed for class I major histocompatibility complex presentation by macrophages but not infected epithelial cells. Immunology 83 (1994) 670-674
32. Chefalo P.J., Grandea A.G., Van Kaer L., and Harding C.V. Tapasin-/- and TAP1-/- macrophages are deficient in vacuolar alternate class I MHC (MHC-I) processing due to decreased MHC-I stability at phagolysosomal pH. J. Immunol. 170 (2003) 5825-5833
33. Flechtner J.B., Cohane K.P., Mehta S., Slusarewicz P., Leonard A.K., Barber B.H., Levey D.L., and Andjelic S. High-affinity interactions between peptides and heat shock protein 70 augment CD8+ T lymphocyte immune responses. J. Immunol. 177 (2006) 1017-1027
34. Yamamoto K., Fujii R., Toyofuku Y., Saito T., Koseki H., Hsu V.W., and Aoe T. The KDEL receptor mediates a retrieval mechanism that contributes to quality control at the endoplasmic reticulum. EMBO J. 20 (2001) 3082-3091
35. Lee R.S., Tartour E., Bruggen P., Vantomme V., Joyeux I., Goud B., Fridman W.H., and Johannes L. Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin. Eur. J. Immunol. 28 (1998) 2726-2737
36. Griffiths S., Ericsson M., Krijnse-Locker J., Nilsson T., Goud B., Soling H.D., Tang B.L., Wong S.H., and Hong W. Localization of the Lys, Asp, Glu, Leu tetrapeptide receptor to the golgi complex and the intermediate compartment in mammalian cells. J. Cell Biol. 127 (1994) 1557-1574
37. Wu Y., and Kipps T.J. Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes. J. Immunol. 159 (1997) 6037-6043
38. Goldberg A.L., Cascio P., Saric T., and Rock K.L. The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol. Immunol. 39 (2002) 147-164
39. Harding C.V., France J., Song R., Farah J.M., and Chatterjee S. M. Iqbal et al. Novel dipeptide aldehydes are proteasome inhibitors and block the MHC-I antigen-processing pathway. J. Immunol. 155 (1995) 1767-1775
40. Sijts A.J., Villanueva M.S., and Pamer E.G. CTL epitope generation is tightly linked to cellular proteolysis of a Listeria monocytogenes antigen. J. Immunol. 156 (1996) 1497-1503
41. Rock K.L., Gramm C., Rothstein L., Clark K., and Stein R. L. Dick et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78 (1994) 761-771
42. Schubert U., Anton L.C., Gibbs J., Norbury C.C., and Yewdell J.W. J.R. Bennink. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404 (2000) 770-774
43. Rodriguez F., Zhang J., and Whitton J.L. DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J. Virol. 71 (1997) 8497-8503
44. Casal J.I., Langeveld J.P., Cortes E., Schaaper W.W., van Dijk E., Vela C., et al. Peptide vaccine against canine parvovirus: identification of two neutralization subsites in the N terminus of VP2 and optimization of the amino acid sequence. J. Virol. 69 (1995) 7274-7277
45. Brinckerhoff L.H., Kalashnikov V.V., Thompson L.W., Yamshchikov G.V., Pierce R.A., Galavotti H.S., et al. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines. Int. J. Cancer 83 (1999) 326-334
46. Liu J., Kjeken R., Mathiesen I., and Barouch D.H. Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation. J. Virol. 82 (2008) 5643-5649
47. Drabick J.J., Glasspool-Malone J., King A., and Malone R.W. Cutaneous transfection and immune responses to intradermal nucleic acid vaccination are significantly enhanced by in vivo electropermeabilization. Mol. Ther. 3 (2001) 249-255
48. Woodberry T., Gardner J., Mateo L., Eisen D., Medveczky J., Ramshaw I.A., Thomson S.A., Ffrench R.A., Elliott S.L., Firat H., Lemonnier F.A., and Suhrbier A. Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8(+) cytotoxic T-cell epitopes. J. Virol. 73 (1999) 5320-5325
49. Thomson S.A., Elliott S.L., Sherritt M.A., Sproat K.W., Coupar B.E., Scalzo A.A., Forbes C.A., Ladhams A.M., Mo X.Y., Tripp R.A., Doherty P.C., Moss D.J., and Suhrbier A. Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. J. Immunol. 157 (1996) 822-826
50. Thomson S.A., Khanna R., Gardner J., Burrows S.R., Coupar B., Moss D.J., and Suhrbier A. Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 5845-5849